CN100430058C - 结晶的2,5-二酮-3-(1-甲基-1h-吲哚-3-基)-4-[1-(吡啶-2-甲基)哌啶-4-基]-1h-吲哚-3-基]-1h-吡咯单盐酸盐 - Google Patents

结晶的2,5-二酮-3-(1-甲基-1h-吲哚-3-基)-4-[1-(吡啶-2-甲基)哌啶-4-基]-1h-吲哚-3-基]-1h-吡咯单盐酸盐 Download PDF

Info

Publication number
CN100430058C
CN100430058C CNB038166216A CN03816621A CN100430058C CN 100430058 C CN100430058 C CN 100430058C CN B038166216 A CNB038166216 A CN B038166216A CN 03816621 A CN03816621 A CN 03816621A CN 100430058 C CN100430058 C CN 100430058C
Authority
CN
China
Prior art keywords
indol
crystalline
salt
methyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB038166216A
Other languages
English (en)
Chinese (zh)
Other versions
CN1668304A (zh
Inventor
J·K·布什
M·M·福尔
S·M·罗伊策尔-埃登斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suoyuan Biomedical Usa Co ltd
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42799191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100430058(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1668304A publication Critical patent/CN1668304A/zh
Application granted granted Critical
Publication of CN100430058C publication Critical patent/CN100430058C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB038166216A 2002-07-12 2003-07-08 结晶的2,5-二酮-3-(1-甲基-1h-吲哚-3-基)-4-[1-(吡啶-2-甲基)哌啶-4-基]-1h-吲哚-3-基]-1h-吡咯单盐酸盐 Expired - Lifetime CN100430058C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39597602P 2002-07-12 2002-07-12
US60/395,976 2002-07-12

Publications (2)

Publication Number Publication Date
CN1668304A CN1668304A (zh) 2005-09-14
CN100430058C true CN100430058C (zh) 2008-11-05

Family

ID=42799191

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038166216A Expired - Lifetime CN100430058C (zh) 2002-07-12 2003-07-08 结晶的2,5-二酮-3-(1-甲基-1h-吲哚-3-基)-4-[1-(吡啶-2-甲基)哌啶-4-基]-1h-吲哚-3-基]-1h-吡咯单盐酸盐

Country Status (21)

Country Link
US (2) US8114901B2 (enExample)
EP (1) EP1523313B1 (enExample)
JP (2) JP4771356B2 (enExample)
KR (1) KR100687165B1 (enExample)
CN (1) CN100430058C (enExample)
AU (1) AU2003280958B9 (enExample)
CA (1) CA2393720C (enExample)
DE (1) DE60317675T2 (enExample)
EA (1) EA007463B1 (enExample)
EC (1) ECSP055537A (enExample)
ES (1) ES2295605T3 (enExample)
HR (1) HRP20050035B1 (enExample)
IL (1) IL165747A (enExample)
NO (1) NO330254B1 (enExample)
NZ (1) NZ537137A (enExample)
PE (1) PE20040652A1 (enExample)
PL (1) PL373046A1 (enExample)
TW (1) TWI315667B (enExample)
UA (1) UA78801C2 (enExample)
WO (1) WO2004006928A1 (enExample)
ZA (1) ZA200500065B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101345002B1 (ko) 2005-01-21 2013-12-31 아스텍스 테라퓨틱스 리미티드 제약 화합물
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2408372B1 (en) 2009-03-02 2019-01-09 Seventh Sense Biosystems, Inc. Devices associated with blood sampling
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
ES2561824T3 (es) 2010-07-16 2016-03-01 Seventh Sense Biosystems, Inc. Ambiente a baja presión para dispositivos de transferencia de fluidos
WO2012044689A1 (en) * 2010-09-30 2012-04-05 Wisconsin Alumni Research Foundation (20R,25S)-2-METHYLENE-19,26-DINOR-1α, 25-DIHYDROXYVITAMIN D3 IN CRYSTALLINE FORM
ES2565805T3 (es) 2010-11-09 2016-04-07 Seventh Sense Biosystems, Inc. Sistemas e interfaces para el muestreo de sangre
KR102237667B1 (ko) 2011-04-29 2021-04-12 세븐쓰 센스 바이오시스템즈, 인크. 유체들의 전달 및/또는 수용
KR20190086655A (ko) 2016-06-17 2019-07-23 유니버시다드 데 로스 안데스 저온-적응된 해양생물종의 천연 공급원으로부터 유래된 젤라틴 중합체 및 그것의 용도
TWI855386B (zh) 2016-08-10 2024-09-11 瑞士商赫孚孟拉羅股份公司 包含Ａｋｔ蛋白質激酶抑制劑之醫藥組合物
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
CN116199590B (zh) * 2022-12-26 2024-12-24 湖北美林药业有限公司 一种盐酸多巴酚丁胺及其注射剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017182A1 (en) * 1993-12-23 1995-06-29 Eli Lilly And Company Protein kinase c inhibitors
CN1288007A (zh) * 1999-07-29 2001-03-21 伊莱利利公司 6－羟基－3－(4－[2－(哌啶－1－基)乙氧基]苯氧基)－2－(4－甲氧基苯基)苯并[b]噻吩盐酸盐的新晶形
WO2001030331A2 (en) * 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
WO2002002116A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor
WO2002002094A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3625738A1 (de) 1986-07-30 1988-02-11 Goedecke Ag 2-acyloxypropylamin-derivate, verfahren zu deren herstellung und deren verwendung
US4785085A (en) 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4808613A (en) 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
DE3752123T2 (de) 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
DE3803620A1 (de) 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
CZ280738B6 (cs) 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
CA2015996C (en) 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
US5380746A (en) 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5292747A (en) 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE4243321A1 (de) 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
SE501711C2 (sv) * 1993-09-08 1995-05-02 Jimek Int Ab Sprayrör för en duktvättanordning vid en tryckpress
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
PE91598A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
RU2004135382A (ru) * 2002-06-05 2005-06-27 Янссен Фармацевтика Н.В. (Be) Замещенные пирролины в качестве ингибиторов киназы

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017182A1 (en) * 1993-12-23 1995-06-29 Eli Lilly And Company Protein kinase c inhibitors
CN1288007A (zh) * 1999-07-29 2001-03-21 伊莱利利公司 6－羟基－3－(4－[2－(哌啶－1－基)乙氧基]苯氧基)－2－(4－甲氧基苯基)苯并[b]噻吩盐酸盐的新晶形
WO2001030331A2 (en) * 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
WO2002002116A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor
WO2002002094A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WO95 17182A 1995.06.29

Also Published As

Publication number Publication date
DE60317675D1 (de) 2008-01-03
IL165747A (en) 2010-05-17
AU2003280958A1 (en) 2004-02-02
HRP20050035A2 (en) 2005-04-30
HK1075839A1 (en) 2005-12-30
AU2003280958B8 (en) 2009-02-19
CA2393720A1 (en) 2004-01-16
EA007463B1 (ru) 2006-10-27
US20050288332A1 (en) 2005-12-29
UA78801C2 (en) 2007-04-25
PE20040652A1 (es) 2004-10-05
TWI315667B (en) 2009-10-11
EP1523313B1 (en) 2007-11-21
KR20050021453A (ko) 2005-03-07
EP1523313A1 (en) 2005-04-20
NO330254B1 (no) 2011-03-14
AU2003280958B2 (en) 2008-12-18
JP2006502115A (ja) 2006-01-19
HRP20050035B1 (hr) 2013-07-31
US20070270465A1 (en) 2007-11-22
NO20050676L (no) 2005-02-09
ES2295605T3 (es) 2008-04-16
JP5242718B2 (ja) 2013-07-24
DE60317675T2 (de) 2008-10-30
WO2004006928A1 (en) 2004-01-22
KR100687165B1 (ko) 2007-02-27
IL165747A0 (en) 2006-01-15
CN1668304A (zh) 2005-09-14
JP4771356B2 (ja) 2011-09-14
CA2393720C (en) 2010-09-14
JP2011144182A (ja) 2011-07-28
EA200500191A1 (ru) 2005-06-30
AU2003280958B9 (en) 2009-07-02
NZ537137A (en) 2007-11-30
TW200408392A (en) 2004-06-01
ECSP055537A (es) 2005-03-10
PL373046A1 (en) 2005-08-08
ZA200500065B (en) 2006-03-29
US8114901B2 (en) 2012-02-14

Similar Documents

Publication Publication Date Title
CN114846006B (zh) 杂环化合物及其制备方法和用途
CN100430058C (zh) 结晶的2,5-二酮-3-(1-甲基-1h-吲哚-3-基)-4-[1-(吡啶-2-甲基)哌啶-4-基]-1h-吲哚-3-基]-1h-吡咯单盐酸盐
CN108779126A (zh) 2-[(2s)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物的结晶形式
US10513513B2 (en) Salts of quinazoline derivative or crystals thereof, and the process for producing thereof
CN114222745B (zh) 活化素受体样激酶抑制剂的盐和晶体形式
KR20210107783A (ko) 선택적 에스트로겐 수용체 분해제의 신규 염
WO2016098070A1 (en) Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
CN116075504B (zh) 化合物的结晶形式
US20070032506A1 (en) Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
HK40072166B (zh) 杂环化合物及其制备方法和用途
CN117794935A (zh) 激酶抑制剂的盐和固体形式
HU231012B1 (hu) Lapatinib sók
MXPA02007150A (es) Monoclorohidrato crsitalino de 2, 5-diona-3-(1-metil -1h-indol-3-il) -4-[1-(piridin-2-ilmetil) piperidin-4-il) -1h-indol-3-il) -1h-pirrol.
HK1075839B (en) Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160301

Address after: California, USA

Patentee after: Denovo Biomedical Co.

Address before: indiana

Patentee before: Eli Lilly and Co.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: Suoyuan biomedical (USA) Co.,Ltd.

Address before: California, USA

Patentee before: Denovo Biomedical Co.

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20081105